Literature DB >> 12200758

Increased rates of lipolysis among human immunodeficiency virus-infected men receiving highly active antiretroviral therapy.

Colleen Hadigan1, Sudhir Borgonha, Jessica Rabe, Vernon Young, Steven Grinspoon.   

Abstract

Human immunodeficiency virus (HIV) lipodystrophy is associated with fat redistribution, dyslipidemia, and insulin resistance; however, the mechanism of insulin resistance remains unknown. We hypothesized that HIV-infected subjects with fat redistribution have increased rates of lipolysis and increased circulating free fatty acid (FFA) levels that contribute to insulin resistance. Anthrompometric and body composition data were obtained and a standard 75-g oral glucose tolerance test (OGTT) was performed on day 1 of the study. Stable isotope infusions of glycerol and palmitate were completed following an overnight fast to assess rates of lipolysis and FFA flux in HIV-infected men (n = 19) with and without fat redistribution and healthy controls (n = 8) on day 2. Total FFA levels after standard glucose challenge were increased among HIV-infected subjects and positively associated with abdominal visceral adipose tissue area. In contrast, fasting total FFA levels were inversely associated with subcutaneous fat area. Rates of basal lipolysis were significantly increased among HIV-infected subjects (rate of appearance [Ra] glycerol, 4.1 +/- 0.2 v 3.3 +/- 0.2 micromol/kg/min in controls; P =.02). Among HIV-infected subjects, use of stavudine (P =.006) and the rate of lipolysis (ie, Ra glycerol, P =.02) were strong positive predictors of insulin resistance as measured by insulin response to glucose challenge, controlling for effects of age, body mass index (BMI), waist-to-hip ratio (WHR), and protease inhibitor (PI) exposure. These data demonstrate increased rates of lipolysis and increased total FFA levels in HIV-infected subjects and suggest that increased lipolysis may contribute to insulin resistance in this patient population. Copyright 2002, Elsevier Science (USA). All rights reserved.

Entities:  

Mesh:

Substances:

Year:  2002        PMID: 12200758     DOI: 10.1053/meta.2002.34704

Source DB:  PubMed          Journal:  Metabolism        ISSN: 0026-0495            Impact factor:   8.694


  38 in total

Review 1.  [Adverse effects of antiretroviral therapy. Aspects of pathogenesis].

Authors:  U Seybold; R Draenert; F D Goebel
Journal:  Internist (Berl)       Date:  2003-06       Impact factor: 0.743

Review 2.  Lipodystrophy: pathophysiology and advances in treatment.

Authors:  Christina G Fiorenza; Sharon H Chou; Christos S Mantzoros
Journal:  Nat Rev Endocrinol       Date:  2010-11-16       Impact factor: 43.330

3.  Improved triglycerides and insulin sensitivity with 3 months of acipimox in human immunodeficiency virus-infected patients with hypertriglyceridemia.

Authors:  Colleen Hadigan; James Liebau; Martin Torriani; Rebecca Andersen; Steven Grinspoon
Journal:  J Clin Endocrinol Metab       Date:  2006-08-29       Impact factor: 5.958

Review 4.  Obesity and Weight Gain in Persons with HIV.

Authors:  Samuel S Bailin; Curtis L Gabriel; Celestine N Wanjalla; John R Koethe
Journal:  Curr HIV/AIDS Rep       Date:  2020-04       Impact factor: 5.071

5.  Viral mechanisms of adipose dysfunction: lessons from HIV-1 Vpr.

Authors:  N Agarwal; A Balasubramanyam
Journal:  Adipocyte       Date:  2014-10-30       Impact factor: 4.534

6.  Combination of niacin and fenofibrate with lifestyle changes improves dyslipidemia and hypoadiponectinemia in HIV patients on antiretroviral therapy: results of "heart positive," a randomized, controlled trial.

Authors:  Ashok Balasubramanyam; Ivonne Coraza; E O'Brian Smith; Lynne W Scott; Payal Patel; Dinakar Iyer; Addison A Taylor; Thomas P Giordano; Rajagopal V Sekhar; Pamela Clark; Edith Cuevas-Sanchez; Swarna Kamble; Christie M Ballantyne; Henry J Pownall
Journal:  J Clin Endocrinol Metab       Date:  2011-05-11       Impact factor: 5.958

7.  HIV-1 Vpr induces adipose dysfunction in vivo through reciprocal effects on PPAR/GR co-regulation.

Authors:  Neeti Agarwal; Dinakar Iyer; Sanjeet G Patel; Rajagopal V Sekhar; Terry M Phillips; Ulrich Schubert; Toni Oplt; Eric D Buras; Susan L Samson; Jacob Couturier; Dorothy E Lewis; Maria C Rodriguez-Barradas; Farook Jahoor; Tomoshige Kino; Jeffrey B Kopp; Ashok Balasubramanyam
Journal:  Sci Transl Med       Date:  2013-11-27       Impact factor: 17.956

8.  Effects of the human immunodeficiency virus-protease inhibitor, ritonavir, on basal and catecholamine-stimulated lipolysis.

Authors:  Diane C Adler-Wailes; Hanguan Liu; Faiyaz Ahmad; Ningping Feng; Constantine Londos; Vincent Manganiello; Jack A Yanovski
Journal:  J Clin Endocrinol Metab       Date:  2005-03-01       Impact factor: 5.958

9.  Altered relationship of plasma triglycerides to HDL cholesterol in patients with HIV/HAART-associated dyslipidemia: further evidence for a unique form of metabolic syndrome in HIV patients.

Authors:  Catherine N Vu; Raul Ruiz-Esponda; Eric Yang; Evelyn Chang; Baiba Gillard; Henry J Pownall; Ron C Hoogeveen; Ivonne Coraza; Ashok Balasubramanyam
Journal:  Metabolism       Date:  2013-03-19       Impact factor: 8.694

10.  Acipimox, an inhibitor of lipolysis, attenuates atherogenesis in LDLR-null mice treated with HIV protease inhibitor ritonavir.

Authors:  Wen Guo; Siu Wong; Jeffrey Pudney; Ravi Jasuja; Ning Hua; Lan Jiang; Andrew Miller; Paul W Hruz; James A Hamilton; Shalender Bhasin
Journal:  Arterioscler Thromb Vasc Biol       Date:  2009-09-17       Impact factor: 8.311

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.